SecBot SecBot

CNXU

Conexeu Sciences Inc.
Nasdaq· CIK 0002066836
$2.96 +0.02 (+0.68%)
Oct 27 4:00 PM ET · prev $2.94
Market cap
$94.0M
Micro cap
Median target
$20.00
+576% · range $20.00–20.00
Since first trade
−77.4%
from $13.07 · May 21
30 days
−21.5%
from $3.77
Range since listing
$2.94–16.85
−82% from high · low Oct 26
Avg volume 20D
356.7K
Oct 14 spike 1.15M
Short interest
🔒 Subscribers only
Insider net
+$662.2K
1 buyer · 0 sellers · 12 mo
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/3
Strongest BEARISH Conexeu Sciences Inc. disclosed multiple unregistered securities sales from September 14 to October 15…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $662.2K. No open-market sales.

  • TrendDOWNTREND

    39% below its 50-day average. New closing low $2.94 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 19.

Who's buying

13F
Top holderSharesValue
UBS Group AG12,264$133.9K
MORGAN STANLEY5,871$64.1K
CITIGROUP INC5,219$57.0K
ROYAL BANK OF CANADA887$10.0K
JONES FINANCIAL COMPANIES LLLP100$1.1K
OSAIC HOLDINGS, INC.100$1.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +576%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jun 22, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Conexeu Sciences Inc. disclosed multiple unregistered securities sales from September 14 to October 15, 2026…
8-K — Impact 6/10
Oct 15, 2026 Press
Conexeu Sciences closed a ~$5M private placement of units (share + warrant) at $3.00/unit, with $250K held in escrow…
Impact 5/10
Oct 15, 2026 Activist
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing
Oct 15, 2026 Insider
Purcell Lynn Sebastian bought 166,666 shares
Director @ $3.00 ($500.0K)
Oct 15, 2026 Insider
Purcell Lynn Sebastian bought 166,666 shares
Director
Oct 6, 2026 Press
Conexeu Sciences provided a regulatory and manufacturing update for its lead wound care device candidate, Ten Minute…
Impact 3/10
Sep 25, 2026 Insider
Bogart David Robert acquired via exercise 750,000 shares
Chief Commercial Officer @ $0.001000 ($750.00)
Jun 29, 2026 SEC
Andrew Costa filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing 50,000 stock options in…
3 — Impact 2/10

Insider ledger

Form 4
$662.2K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 15, 2026
Purcell Lynn Sebastian
Director
BUY$500.0K
Oct 15, 2026
Purcell Lynn Sebastian
Director
BUY166,666 sh
Sep 25, 2026
Bogart David Robert
Chief Commercial Officer
EXERCISE$750.00
Sep 14, 2026
Sharpe Jeffrey Nathan
Director
EXERCISE$500.00
Sep 4, 2026
Purcell Lynn Sebastian
Director
EXERCISE$500.5K
Sep 4, 2026
Purcell Lynn Sebastian
Director
EXERCISE$217.61
Jun 18, 2026
Wright Michael G.
10%+ Owner
EXERCISE$250.00
Jun 18, 2026
Purcell Lynn Sebastian
Director
BUY$162.0K

Earnings setup

Estimates
−$0.11
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.11-$0.11–-$0.11—$0.00
Next Q-$0.12-$0.12–-$0.12—$0.00
Current FY-$0.40-$0.40–-$0.40—$0.00
Next FY-$0.53-$0.53–-$0.53—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Activist
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors
Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical…
Oct 6, 2026
FDA
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device…
Aug 18, 2026
Press release
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of…
Jul 15, 2026
Press release
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) is aiming its investigational CXU™ platform at the largest unclaimed…
Jun 25, 2026
Press release
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the…
Reddit
Recent posts
r/investing_discussion Neutral 8d ago
Does Conexeu make a better move by targeting wound care first?
1 upvotes · 0 comments
All social signals and their track records

SecBot reports

4 filings · 3 press releases · 0 bullish · 1 bearish · 3 neutral
All CNXU filing & press-release reports (7)